학술논문

FDA Approval Summary: Tremelimumab in Combination with Durvalumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma
Document Type
Article
Source
In: Clinical Cancer Research. (Clinical Cancer Research, 15 January 2024, 30(2):269-273)
Subject
Language
English
ISSN
15573265
10780432